Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression—Inhibitory effects of anti-inflammatory drugs
Identifieur interne : 002560 ( Main/Exploration ); précédent : 002559; suivant : 002561Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression—Inhibitory effects of anti-inflammatory drugs
Auteurs : Bettina Wedi [Allemagne] ; Vera Novacovic [Allemagne] ; Michael Koerner [Allemagne] ; Alexander Kapp [Allemagne]Source :
- The Journal of Allergy and Clinical Immunology [ 0091-6749 ] ; 2000.
English descriptors
- KwdEn :
- ASST:, AT:, CD63, CU:, Chronic urticaria, DAT:, DNAT:, FcϵRI:, HR:, NAT:, SLT:, autoantibodies, fMLP:, histamine release, sulfidoleukotrienes.
- Teeft :
- Acta derm venereol, Allergy, Allergy clin immunol, Allergy clin immunol march, Allergy clin immunol volume, Angioedema, Assay systems, Asst, Asterisk, Atopic, Atopic controls, Atopic donor, Autoantibody, Autoimmune, Autoimmune urticaria, Autologous, Basophil, Basophil activation marker, Chloroquine, Chronic idiopathic urticaria, Chronic urticaria, Clin, Daily symptoms, Dapsone, Dermatitis, Dermatitis herpetiformis, Dermatol, Dnat, Donor, Fmlp, Greaves, Histamine, Histamine release, Hypocomplementemic urticarial vasculitis syndrome, Immunol, Leukocyte, Leukocyte suspensions, Lidocaine, Mast cells, Mizolastine, Negative asst, Negative asst results, Negative control, Neutrophil, Nonatopic, Nonatopic donor, Open bars, Positive asst, Positive asst results, Serum, Serum activity, Significant correlation, Solid bars, Statistical significance, Surface expression, Tetanus toxoid, Urticaria, Urticarial, Wedi, Whole blood.
Abstract
Abstract: Background: A role of potential histamine-releasing autoantibodies against the high-affinity IgE receptor on the surface of basophils and mast cells is discussed in the pathogenesis of chronic urticaria. This so-called autoimmune urticaria may be diagnosed by a positive intracutaneous autologous serum skin test, which is found in about 30% of patients with chronic urticaria. Objective: Our purpose was, first, to compare the effect of complement-inactivated sera of 20 patients with chronic urticaria and positive autologous serum skin tests, 20 patients with chronic urticaria and negative skin tests, and 20 control subjects without chronic urticaria (10 atopic and 10 nonatopic subjects) and, second, to analyze the effect of anti-inflammatory drugs on the serum activity. Methods: The following assay systems were used: release of histamine in whole blood samples, surface expression of the activation marker CD63 on basophils, and sulfidoleukotriene de novo production in leukocyte suspensions. Whole blood, basophils, and leukocyte suspensions were obtained from a nonatopic and an atopic donor. Results: Sera of patients with autologous serum skin test positive chronic urticaria resulted not only in significantly increased histamine release compared with skin test–negative chronic urticaria sera but also in a significant higher induction of basophil CD63 surface expression and sulfidoleukotriene de novo production. However, serum activity was neither characteristic for chronic urticaria nor for chronic urticaria with a positive autologous serum skin test. Preincubation with dapsone, chloroquine, and lidocaine dose dependently resulted in a significant reduction of all histamine release, CD63 expression, and sulfidoleukotriene production. In addition, mizolastine was able to inhibit serum-induced sulfidoleukotriene production. Conclusion: Further studies investigating the in vivo effect of these drugs will have to clarify their role in the management of the subset of patients with chronic urticaria demonstrating serum-induced inflammatory effects. (J Allergy Clin Immunol 2000;105:552-60.)
Url:
DOI: 10.1067/mai.2000.104939
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000083
- to stream Istex, to step Curation: 000083
- to stream Istex, to step Checkpoint: 001378
- to stream Main, to step Merge: 002588
- to stream Main, to step Curation: 002560
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression—Inhibitory effects of anti-inflammatory drugs</title><author><name sortKey="Wedi, Bettina" sort="Wedi, Bettina" uniqKey="Wedi B" first="Bettina" last="Wedi">Bettina Wedi</name></author><author><name sortKey="Novacovic, Vera" sort="Novacovic, Vera" uniqKey="Novacovic V" first="Vera" last="Novacovic">Vera Novacovic</name></author><author><name sortKey="Koerner, Michael" sort="Koerner, Michael" uniqKey="Koerner M" first="Michael" last="Koerner">Michael Koerner</name></author><author><name sortKey="Kapp, Alexander" sort="Kapp, Alexander" uniqKey="Kapp A" first="Alexander" last="Kapp">Alexander Kapp</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D15E8B357147DECFC0FE189F98C5C0EDD4859D7</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1067/mai.2000.104939</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-9Q0F9NDR-R/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000083</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000083</idno><idno type="wicri:Area/Istex/Curation">000083</idno><idno type="wicri:Area/Istex/Checkpoint">001378</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001378</idno><idno type="wicri:doubleKey">0091-6749:2000:Wedi B:chronic:urticaria:serum</idno><idno type="wicri:Area/Main/Merge">002588</idno><idno type="wicri:Area/Main/Curation">002560</idno><idno type="wicri:Area/Main/Exploration">002560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression—Inhibitory effects of anti-inflammatory drugs</title><author><name sortKey="Wedi, Bettina" sort="Wedi, Bettina" uniqKey="Wedi B" first="Bettina" last="Wedi">Bettina Wedi</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology and Allergology, Hannover Medical University, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Novacovic, Vera" sort="Novacovic, Vera" uniqKey="Novacovic V" first="Vera" last="Novacovic">Vera Novacovic</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology and Allergology, Hannover Medical University, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Koerner, Michael" sort="Koerner, Michael" uniqKey="Koerner M" first="Michael" last="Koerner">Michael Koerner</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology and Allergology, Hannover Medical University, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Kapp, Alexander" sort="Kapp, Alexander" uniqKey="Kapp A" first="Alexander" last="Kapp">Alexander Kapp</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology and Allergology, Hannover Medical University, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Allergy and Clinical Immunology</title><title level="j" type="abbrev">YMAI</title><idno type="ISSN">0091-6749</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">105</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="552">552</biblScope><biblScope unit="page" to="560">560</biblScope></imprint><idno type="ISSN">0091-6749</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-6749</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>ASST:</term><term>AT:</term><term>CD63</term><term>CU:</term><term>Chronic urticaria</term><term>DAT:</term><term>DNAT:</term><term>FcϵRI:</term><term>HR:</term><term>NAT:</term><term>SLT:</term><term>autoantibodies</term><term>fMLP:</term><term>histamine release</term><term>sulfidoleukotrienes</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acta derm venereol</term><term>Allergy</term><term>Allergy clin immunol</term><term>Allergy clin immunol march</term><term>Allergy clin immunol volume</term><term>Angioedema</term><term>Assay systems</term><term>Asst</term><term>Asterisk</term><term>Atopic</term><term>Atopic controls</term><term>Atopic donor</term><term>Autoantibody</term><term>Autoimmune</term><term>Autoimmune urticaria</term><term>Autologous</term><term>Basophil</term><term>Basophil activation marker</term><term>Chloroquine</term><term>Chronic idiopathic urticaria</term><term>Chronic urticaria</term><term>Clin</term><term>Daily symptoms</term><term>Dapsone</term><term>Dermatitis</term><term>Dermatitis herpetiformis</term><term>Dermatol</term><term>Dnat</term><term>Donor</term><term>Fmlp</term><term>Greaves</term><term>Histamine</term><term>Histamine release</term><term>Hypocomplementemic urticarial vasculitis syndrome</term><term>Immunol</term><term>Leukocyte</term><term>Leukocyte suspensions</term><term>Lidocaine</term><term>Mast cells</term><term>Mizolastine</term><term>Negative asst</term><term>Negative asst results</term><term>Negative control</term><term>Neutrophil</term><term>Nonatopic</term><term>Nonatopic donor</term><term>Open bars</term><term>Positive asst</term><term>Positive asst results</term><term>Serum</term><term>Serum activity</term><term>Significant correlation</term><term>Solid bars</term><term>Statistical significance</term><term>Surface expression</term><term>Tetanus toxoid</term><term>Urticaria</term><term>Urticarial</term><term>Wedi</term><term>Whole blood</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Background: A role of potential histamine-releasing autoantibodies against the high-affinity IgE receptor on the surface of basophils and mast cells is discussed in the pathogenesis of chronic urticaria. This so-called autoimmune urticaria may be diagnosed by a positive intracutaneous autologous serum skin test, which is found in about 30% of patients with chronic urticaria. Objective: Our purpose was, first, to compare the effect of complement-inactivated sera of 20 patients with chronic urticaria and positive autologous serum skin tests, 20 patients with chronic urticaria and negative skin tests, and 20 control subjects without chronic urticaria (10 atopic and 10 nonatopic subjects) and, second, to analyze the effect of anti-inflammatory drugs on the serum activity. Methods: The following assay systems were used: release of histamine in whole blood samples, surface expression of the activation marker CD63 on basophils, and sulfidoleukotriene de novo production in leukocyte suspensions. Whole blood, basophils, and leukocyte suspensions were obtained from a nonatopic and an atopic donor. Results: Sera of patients with autologous serum skin test positive chronic urticaria resulted not only in significantly increased histamine release compared with skin test–negative chronic urticaria sera but also in a significant higher induction of basophil CD63 surface expression and sulfidoleukotriene de novo production. However, serum activity was neither characteristic for chronic urticaria nor for chronic urticaria with a positive autologous serum skin test. Preincubation with dapsone, chloroquine, and lidocaine dose dependently resulted in a significant reduction of all histamine release, CD63 expression, and sulfidoleukotriene production. In addition, mizolastine was able to inhibit serum-induced sulfidoleukotriene production. Conclusion: Further studies investigating the in vivo effect of these drugs will have to clarify their role in the management of the subset of patients with chronic urticaria demonstrating serum-induced inflammatory effects. (J Allergy Clin Immunol 2000;105:552-60.)</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Basse-Saxe</li></region><settlement><li>Hanovre</li></settlement></list><tree><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Wedi, Bettina" sort="Wedi, Bettina" uniqKey="Wedi B" first="Bettina" last="Wedi">Bettina Wedi</name></region><name sortKey="Kapp, Alexander" sort="Kapp, Alexander" uniqKey="Kapp A" first="Alexander" last="Kapp">Alexander Kapp</name><name sortKey="Koerner, Michael" sort="Koerner, Michael" uniqKey="Koerner M" first="Michael" last="Koerner">Michael Koerner</name><name sortKey="Novacovic, Vera" sort="Novacovic, Vera" uniqKey="Novacovic V" first="Vera" last="Novacovic">Vera Novacovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8D15E8B357147DECFC0FE189F98C5C0EDD4859D7
|texte= Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression—Inhibitory effects of anti-inflammatory drugs
}}
| This area was generated with Dilib version V0.6.33. |  |